PM
Paite Meisheng
China · Biotech · Healthtech
Paite Meisheng develops medicines and formulations for pet health.
Product
Paite Meisheng develops veterinary medicines for pets, combining drug discovery with formulation development and veterinary clinical expertise. Its research includes new drugs and treatments for parasitic, age-related, cancer and immune diseases.
Founded in Nanjing in 2023, the company also develops pet health products through its subsidiary Pairuile. Its first innovative veterinary medicine had entered clinical development by July 2026.
Funding history
2 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | CITIC Group Agricultural Industry Fund — LeadFuture Pet Research Institute — Participant | |
| Financing | Undisclosed | Triwise Capital — Participant |
Investors
CITIC Group Agricultural Industry FundLed Series AFuture Pet Research InstituteJoined Series ATriwise CapitalJoined FinancingCoverage
weeklyWeekly funding picks, July 6–12: lithium offtake, grid flexibility and antibody researchJul 9, 2026Paite Meisheng · Series AFeb 5, 2026Paite Meisheng · FinancingSimilar companies
BMBoston Medical SciencesBoston Medical Sciences develops AI-assisted colorectal cancer screening technology.¥5.6B · Series B
SSSunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A